{"classes":[{"categories":[{"measurements":[{"comment":"Due to the condition of the blood samples analytical results were unable to be interpreted. As such, data is not available and mean CD4 T cell results have been identified as 'NA'.","groupId":"OG000","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The relative difference in CD4 T cell counts before and after administration of the TT booster vaccine (Day 8) will be compared. The number of cells per microliter (cells/µL) will be determined. The proportion of at least 3-fold increase will be reported along with its 95% CI. The actual magnitude of change will be examined by taking a log scale of CD4 counts and report a mean of change on CD4 on its log scale along with its 95% CI.","dispersionType":"Standard Deviation","groups":[{"description":"Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT\n\nGemcitabine: Gemcitabine will be administered on days 1, 8, 15 every 28 days\n\nTT vaccine booster: One human TT childhood vaccine booster will be administered on day 8","id":"OG000","title":"Gemcitabine With TT Vaccine Booster"}],"paramType":"MEAN","populationDescription":"Blood samples were collected and analyzed by flow cytometry as well as by ELISPOT.","reportingStatus":"POSTED","timeFrame":"Day 8","title":"Change in CD4 T Cell Responses Before TT Booster","type":"PRIMARY","unitOfMeasure":"cells/uL"}